Fatal gene-editing clinical trial in China prompts ethical and regulatory scrutiny

A clinical trial involving gene-editing technology in China has resulted in a fatality, triggering concerns regarding oversight and ethical standards in the region's biotech sector. The incident highlights potential risks in experimental genetic therapies and may lead to stricter regulatory requirements for future trials.